Kunming Pharmaceutical Group announced that the company's Luotai® Hesetong softgels and its holding subsidiaries Lijiangwang® Hesetong softgels and Luotai® Hesetong drops have been newly included in the “National Essential Drug Catalogue”. Currently, the company has 57 products included in this catalog, including 3 new products. In 2025, the company's sales revenue for Hesetong softgels and drip pills was about 902 million yuan, accounting for 13.72% of the company's revenue. This inclusion will help expand the product market, but due to various factors, there is still uncertainty about future sales volume.

Kunming Pharmaceutical Group announced that the company's Luotai® Hesetong softgels and its holding subsidiaries Lijiangwang® Hesetong softgels and Luotai® Hesetong drops have been newly included in the “National Essential Drug Catalogue”. Currently, the company has 57 products included in this catalog, including 3 new products. In 2025, the company's sales revenue for Hesetong softgels and drip pills was about 902 million yuan, accounting for 13.72% of the company's revenue. This inclusion will help expand the product market, but due to various factors, there is still uncertainty about future sales volume.